Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Closes Aquisition of Epoch for $97 Million; Epoch Ends Nasdaq Listing

NEW YORK, Dec. 17 (GenomeWeb News) - Nanogen yesterday closed its acquisition of Epoch Biosciences for $97 million. The deal was originally announced in September, and was approved by shareholders on Dec. 15.

 

Epoch Biosciences ceased trading on the Nasdaq exchange at market close on Thursday.

 

Nanogen shareholders approved the issuance of shares of common stock for the deal, and also approved an amendment to the company's certificate of incorporation increasing the number of authorized shares of Nanogen common stock to 135 million shares.

 

Epoch stockholders will receive .47 shares of Nanogen stock in exchange for each share of Epoch common stock they hold. At the completion of the merger, Nanogen will have approximately 50 million common shares outstanding.

 

The Nanogen shareholder meeting was originally held on Dec. 8, but was postponed until Dec. 15 because the number of shares represented by votes or votes by proxy was insufficient for a decision.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.